.
.
sections
.
![]()
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.while all of the drugs work on cgrp, they don�t all work the same way. three of them target the cgrp molecule itself. aimovig goes after cgrp's receptor in the brain.
https://grassfed.us/Kubala-brother-of-Geisel-from-Hgersten